低分子肝素联合泼尼松治疗小儿肾病综合征的效果、相关临床指标及预后分析

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (352 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical effects, relevant indicators and prognosis of Low Molecular Heparin Combined with Prednisone in the treatment of children with nephrotic syndrome. Methods Clinical data of 84 children confirmed to be with nephrotic syndrome in Affiliated Hospital of Inner Mongolia Medical University were analyzed from January 2016 to January 2017, and they were divided into two groups according to different treatment methods applied: 42 cases were given only Low Molecular Heparin for treatment as control group, while the other 42 children were treated with Low Molecular Heparin combined with Prednisone as observation group. The clinical indicators including coagulation indicators, total cholesterol, plasma albumin and 24-h proteinuria, renal function after prognosis, and life quality were compared between two groups for one month after treatment. Results The time for activation of partial thromboplastin and prothrombin, incidence rate of adverse reactions between two groups were compared, with no statistical differences (P > 0.05). After treatment, serum total cholesterol and 24-h proteinuria levels of observation group were both lower than those of control group, and plasma albumin of observation group was higher than that of control group, the differences were statistically significant (P < 0.01). After treatment, the creatinine clearance rate and quality of life scores in observation group were higher than those in control group, urea nitrogen, serum creatinine in observation group were lower than those in control group, the differences were statistically significant (P < 0.01). Conclusion Children with nephrotic syndrome are treated with Low Molecular Heparin combined with Prednisone, these treatment will improve the curative effect, and reduce adverse reaction, but also promote the prognosis effect. Therefore, this therapy is significant value to be popularized in clinical application and for research.

Key words： Nephrotic syndrome Children Prednisone Low Molecular Heparin Adverse reaction Renal function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TIAN Jianmei1 LIU Xiaowei2

Cite this article:

TIAN Jianmei1 LIU Xiaowei2. Effect, relevant clinical indicators and prognosis analysis of Low Molecular Heparin combined with Prednisone in the treatment of children with nephrotic syndrome[J]. 中国医药导报, 2017, 14(24): 147-150.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I24/147

[1] 谭静，吴银，郭明好.胸腺肽α1对激素耐药型肾病综合征患儿细胞免疫功能的影响[J].中华实用儿科临床杂志，2014，29（5）：399-400.
[2] 周瑜，李科玉.羟乙基淀粉联合呋塞米治疗小儿肾病综合征合并重度水肿的临床研究[J].检验医学与临床，2016， 13（22）：3161-3162，3165.
[3] Cevik L，Karaca RO，Babaoglu MO，et al. Letter to the editor regarding'Youssef et al.'s multi-drug resistance-1 gene polymorphisms in nephrotic syndrome：impact on susceptibility and response to steroids' [J]. Gene，2014，537（1）：174.
[4] Yoshikawa N，Norishige R，Nakanishi K，et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment [J]. Kidney Int，2015， 87（1）：225-232.
[5] Sinha A，Saha A，Kumar M，et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome [J]. Kidney Int，2015，87（1）：217-224.
[6] Muso E，Mune M，Hirano T，et al. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome：evidence from the short-term results from the POLARIS Study [J]. Clin Exp Nephrol，2015， 19（3）：379-386.
[7] 梅长林.肾病综合征[M].北京：科学出版社，2012：1-689.
[8] 刘立春，李祥敏，田雅霞，等.高低临床依从性终末期肾病患者腹膜透析治疗结局和生活质量的对比研究[J].中华行为医学与脑科学杂志，2014，23（7）：622-624.
[9] Moist LM，Troyanov S，White CT，et al. Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis：management of nephrotic syndrome in children [J]. Am J Kidney Dis，2014， 63（3）：354-362.
[10] Bull KR，Mason T，Rimmer AJ，et al. Next-generation sequencing to dissect hereditary nephrotic syndrome in mice identifies a hypomorphic mutation in Lamb2 and models Pierson's syndrome [J]. J Pathol，2014，233（1）：18-26.
[11] Cybulsky AV，Walsh M，Knoll G，et al. Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis：management of glomerulonephritis in adults [J]. Am J Kidney Dis，2014， 63（3）：363-377.
[12] 郑立平，李润娥，武超，等.低分子肝素联合注射用甲泼尼龙琥珀酸钠治疗肾病综合征的药学监护[J].临床合理用药杂志，2015，8（22）：62-63.
[13] 韩婷婷，张碧丽.血清和尿转化生长因子β1、白细胞介素-18、中性粒细胞明胶酶相关脂质运载蛋白水平对激素耐药型肾病综合征的预测作用[J].中华实用儿科临床杂志，2015，30（5）：389-391.
[14] 周发为，游文忠，覃仕锋，等.小儿激素敏感型肾病综合征血清中IL-4、IL-5、TGF-β与IL-10水平变化及意义[J].中国免疫学杂志，2014，30（5）：673-676.
[15] 廖冰，杨帆，蒋东波，等.甲强龙联合低分子肝素治疗原发性肾病综合征临床分析[J].四川医学，2014，35（9）：1168-1170.
[16] 李志辉，林芝，段翠蓉，等.泼尼松联合霉酚酸酯与环孢霉素A治疗儿童激素耐药型肾病综合征的疗效比较[J].中国当代儿科杂志，2016，18（2）：130-135.
[17] 陈小群，彭丽珠.甲泼尼龙冲击与口服足量泼尼松对小儿肾病综合征的疗效及不良反应[J].中国医学创新，2016， 13（11）：115-117.
[18] 宋其蔓.辛伐他汀与低分子肝素联合用药方案治疗肾病综合征的临床研究[J].中国现代药物应用，2015，9（4）：94-95.
[19] 杨亚娜.低分子肝素联合小剂量尿激酶用药方案治疗肾病综合征的临床疗效观察[J].中国卫生标准管理，2015， 6（2）：74-75.
[20] 郑立平，李润娥，武超，等.低分子肝素联合注射用甲泼尼龙琥珀酸钠治疗肾病综合征的药学监护[J].临床合理用药杂志，2015，8（22）：62-63.